Details of the Drug

General Information of Drug (ID: DM0DTF7)

• Drug Name: Zonisamide
• Synonyms: Exceglan; Excegram; Excegran; Tremode; Trerief; Zonegran; Zonisamida; Zonisamidum; Elan brand of zonisamide; Zonisamida [Spanish]; Zonisamide monosodium; Zonisamidum [Latin]; AD 810; PD 110843; SPR_2; AD-810; AD-810N; E-2090; Excegran (TN); PD-110843; Zonegran (TN); Zonegran, Zonisamide; Zonisamide (ZNS); Zonisamide (JAN/USAN/INN); Zonisamide [USAN:BAN:INN:JAN]; 1,2-Benzisoxazole-3-methanesulfonamide; 1,2-benzoxazol-3-ylmethanesulfonamide; 1-(1,2-Benzoxazol-3-Yl)methanesulfonamide; 1-(1,2-benzisoxazol-3-yl)methanesulfonamide; 3-(Sulfamoylmethyl)-1,2-benzisoxazole; 3-sulfamoylmethyl-1,2-benzisoxazole

Indication

Disease Entry	ICD 11	Status	REF
Alcohol dependence	6C40.2	Approved	[1]
Alcohol use disorder	6C40.2	Approved	[1]
Bipolar disorder	6A60	Approved	[1]
Epilepsy	8A60-8A68	Approved	[2]

• Therapeutic Class: Analgesics
• Affected Organisms: Humans and other mammals
• ATC Code:
  N03AX15: Zonisamide
  N03AX: Other antiepileptics
  N03A: ANTIEPILEPTICS
  N03: ANTIEPILEPTICS
  N: NERVOUS SYSTEM
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 212.23
  Logarithm of the Partition Coefficient (xlogp); 0.2
  Rotatable Bond Count (rotbonds); 2
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 5
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
  Bioavailability: 99% of drug becomes completely available to its intended biological destination(s) [4]
  Elimination: 22% of drug is excreted from urine in the unchanged form [3]
  Half-life: The concentration or amount of drug in body reduced by one-half in 63 hours [5]
  Metabolism: The drug is metabolized via the hepatic []
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 40.3875 micromolar/kg/day [6]
  Vd: The volume of distribution (Vd) of drug is 1.45 L/kg []
  Water Solubility: The ability of drug to dissolve in water is measured as 0.8 mg/mL [3]
• Chemical Identifiers:
  Formula: C8H8N2O3S
  IUPAC Name: 1,2-benzoxazol-3-ylmethanesulfonamide
  Canonical SMILES: C1=CC=C2C(=C1)C(=NO2)CS(=O)(=O)N
  InChI: InChI=1S/C8H8N2O3S/c9-14(11,12)5-7-6-3-1-2-4-8(6)13-10-7/h1-4H,5H2,(H2,9,11,12)
  InChIKey: UBQNRHZMVUUOMG-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 5734
  CAS Number: 68291-97-4
  UNII: 459384H98V
  DrugBank ID: DB00909
  TTD ID: D09ZIS
  INTEDE ID: DR1737
  ACDINA ID: D00745
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Sodium channel unspecific (NaC)	TTRK8B9	NOUNIPROTAC	Blocker	[7]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4) Main DME	DE4LYSA	CP3A4_HUMAN	Substrate	[8]
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DEYGVN4	UD11_HUMAN	Substrate	[9]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[10]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[11]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Substrate	[12]
Aldehyde oxidase (AOX)	DE8UGTM	A0A1V9IQJ2_CLOSG	Substrate	[13]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Tyrosine 3-monooxygenase (TH)	OT6ZORKP	TY3H_HUMAN	Gene/Protein Processing	[14]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Zonisamide

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Cenobamate	DM8KLU9	Moderate	Increased metabolism of Zonisamide caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[15]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Zonisamide caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[15]
Fosphenytoin	DMOX3LB	Moderate	Increased metabolism of Zonisamide caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[15]
Phenobarbital	DMXZOCG	Moderate	Increased metabolism of Zonisamide caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[15]

Coadministration of a Drug Treating the Disease Different from Zonisamide (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Moderate	Increased metabolism of Zonisamide caused by Ivosidenib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[15]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Zonisamide caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[15]
Mepyramine	DMB4SFH	Major	Increased risk of hyperpyrexia by the combination of Zonisamide and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[16]
Phenyltoloxamine	DMKAEQW	Major	Additive CNS depression effects by the combination of Zonisamide and Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[16]
Dronedarone	DMA8FS5	Moderate	Decreased metabolism of Zonisamide caused by Dronedarone mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[15]
Nifedipine	DMSVOZT	Moderate	Decreased metabolism of Zonisamide caused by Nifedipine mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[15]
Posaconazole	DMUL5EW	Moderate	Decreased metabolism of Zonisamide caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[15]
Desipramine	DMT2FDC	Major	Increased risk of hyperpyrexia by the combination of Zonisamide and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[16]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Zonisamide caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[15]
Clarithromycin	DM4M1SG	Moderate	Decreased metabolism of Zonisamide caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[15]
Troleandomycin	DMUZNIG	Moderate	Decreased metabolism of Zonisamide caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[15]
Telithromycin	DMZ4P3A	Moderate	Decreased metabolism of Zonisamide caused by Telithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[17]
Cariprazine	DMJYDVK	Major	Increased risk of hyperpyrexia by the combination of Zonisamide and Cariprazine.	Bipolar disorder [6A60]	[16]
Pexidartinib	DMS2J0Z	Moderate	Increased metabolism of Zonisamide caused by Pexidartinib mediated induction of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[15]
Lapatinib	DM3BH1Y	Moderate	Decreased metabolism of Zonisamide caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[18]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Zonisamide caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[15]
Levomilnacipran	DMV26S8	Moderate	Antagonize the effect of Zonisamide when combined with Levomilnacipran.	Chronic pain [MG30]	[19]
Osilodrostat	DMIJC9X	Moderate	Decreased metabolism of Zonisamide caused by Osilodrostat mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[15]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Zonisamide caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[15]
Sertraline	DM0FB1J	Moderate	Antagonize the effect of Zonisamide when combined with Sertraline.	Depression [6A70-6A7Z]	[19]
Cyclobenzaprine	DM1YBRM	Major	Increased risk of hyperpyrexia by the combination of Zonisamide and Cyclobenzaprine.	Depression [6A70-6A7Z]	[16]
Vilazodone	DM4LECQ	Moderate	Antagonize the effect of Zonisamide when combined with Vilazodone.	Depression [6A70-6A7Z]	[19]
Nefazodone	DM4ZS8M	Moderate	Decreased metabolism of Zonisamide caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[15]
Vortioxetine	DM6F1PU	Moderate	Antagonize the effect of Zonisamide when combined with Vortioxetine.	Depression [6A70-6A7Z]	[19]
Milnacipran	DMBFE74	Moderate	Antagonize the effect of Zonisamide when combined with Milnacipran.	Depression [6A70-6A7Z]	[19]
Escitalopram	DMFK9HG	Moderate	Antagonize the effect of Zonisamide when combined with Escitalopram.	Depression [6A70-6A7Z]	[19]
Desvenlafaxine	DMHD4PE	Moderate	Antagonize the effect of Zonisamide when combined with Desvenlafaxine.	Depression [6A70-6A7Z]	[19]
OPC-34712	DMHG57U	Major	Increased risk of hyperpyrexia by the combination of Zonisamide and OPC-34712.	Depression [6A70-6A7Z]	[16]
Clomipramine	DMINRKW	Major	Increased risk of hyperpyrexia by the combination of Zonisamide and Clomipramine.	Depression [6A70-6A7Z]	[16]
Doxepin	DMPI98T	Major	Increased risk of hyperpyrexia by the combination of Zonisamide and Doxepin.	Depression [6A70-6A7Z]	[16]
Maprotiline	DMPWB7T	Major	Increased risk of hyperpyrexia by the combination of Zonisamide and Maprotiline.	Depression [6A70-6A7Z]	[16]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Zonisamide and Esketamine.	Depression [6A70-6A7Z]	[20]
Mepenzolate	DM8YU2F	Major	Additive CNS depression effects by the combination of Zonisamide and Mepenzolate.	Digestive system disease [DE2Z]	[16]
Oxybutynine	DMJPBAX	Major	Increased risk of hyperpyrexia by the combination of Zonisamide and Oxybutynine.	Discovery agent [N.A.]	[16]
Diphenhydramine	DMKQTBA	Major	Increased risk of hyperpyrexia by the combination of Zonisamide and Diphenhydramine.	Episodic vestibular syndrome [AB31]	[16]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Zonisamide caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[15]
Solifenacin	DMG592Q	Major	Increased risk of hyperpyrexia by the combination of Zonisamide and Solifenacin.	Functional bladder disorder [GC50]	[16]
Tolterodine	DMSHPW8	Major	Increased risk of hyperpyrexia by the combination of Zonisamide and Tolterodine.	Functional bladder disorder [GC50]	[16]
Itraconazole	DMCR1MV	Moderate	Decreased metabolism of Zonisamide caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[15]
Miconazole	DMPMYE8	Moderate	Decreased metabolism of Zonisamide caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[15]
Ketoconazole	DMPZI3Q	Moderate	Decreased metabolism of Zonisamide caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[15]
Sulfinpyrazone	DMEV954	Moderate	Increased metabolism of Zonisamide caused by Sulfinpyrazone mediated induction of CYP450 enzyme.	Gout [FA25]	[15]
Boceprevir	DMBSHMF	Moderate	Decreased metabolism of Zonisamide caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[15]
Telaprevir	DMMRV29	Moderate	Decreased metabolism of Zonisamide caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[15]
Rifampin	DMA8J1G	Moderate	Increased metabolism of Zonisamide caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[15]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Zonisamide caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[15]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Zonisamide caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[15]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Zonisamide caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[21]
Belladonna	DM2RBWK	Major	Increased risk of hyperpyrexia by the combination of Zonisamide and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[16]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Zonisamide caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[15]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Zonisamide caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[15]
ITI-007	DMUQ1DO	Major	Increased risk of hyperpyrexia by the combination of Zonisamide and ITI-007.	Insomnia [7A00-7A0Z]	[16]
Crizotinib	DM4F29C	Moderate	Decreased metabolism of Zonisamide caused by Crizotinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[15]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Zonisamide caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[22]
Ceritinib	DMB920Z	Moderate	Decreased metabolism of Zonisamide caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[15]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Zonisamide caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[15]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Zonisamide caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[15]
Hydroxychloroquine	DMSIVND	Moderate	Antagonize the effect of Zonisamide when combined with Hydroxychloroquine.	Malaria [1F40-1F45]	[20]
Idelalisib	DM602WT	Moderate	Decreased metabolism of Zonisamide caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[15]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Zonisamide caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[15]
Vemurafenib	DM62UG5	Moderate	Increased metabolism of Zonisamide caused by Vemurafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[15]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Zonisamide caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[15]
Danazol	DML8KTN	Moderate	Decreased metabolism of Zonisamide caused by Danazol mediated inhibition of CYP450 enzyme.	Menstrual cycle bleeding disorder [GA20]	[15]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Zonisamide and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[23]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Zonisamide and Lasmiditan.	Migraine [8A80]	[24]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Zonisamide caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[25]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Zonisamide and Flibanserin.	Mood disorder [6A60-6E23]	[26]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Zonisamide and Thalidomide.	Multiple myeloma [2A83]	[27]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Zonisamide caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[15]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Zonisamide caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[28]
Dasatinib	DMJV2EK	Moderate	Decreased metabolism of Zonisamide caused by Dasatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[29]
Phenindamine	DMDTC7R	Major	Additive CNS depression effects by the combination of Zonisamide and Phenindamine.	Nasopharyngitis [CA00]	[16]
Dimenhydrinate	DM264B3	Major	Increased risk of hyperpyrexia by the combination of Zonisamide and Dimenhydrinate.	Nausea/vomiting [MD90]	[16]
Promethazine	DM6I5GR	Major	Increased risk of hyperpyrexia by the combination of Zonisamide and Promethazine.	Nausea/vomiting [MD90]	[16]
Cyclizine	DM9G7BS	Major	Increased risk of hyperpyrexia by the combination of Zonisamide and Cyclizine.	Nausea/vomiting [MD90]	[16]
Netupitant	DMEKAYI	Moderate	Decreased metabolism of Zonisamide caused by Netupitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[15]
Entrectinib	DMMPTLH	Moderate	Decreased metabolism of Zonisamide caused by Entrectinib mediated inhibition of CYP450 enzyme.	Non-small cell lung cancer [2C25]	[15]
Levomethadyl Acetate	DM06HG5	Major	Additive CNS depression effects by the combination of Zonisamide and Levomethadyl Acetate.	Opioid use disorder [6C43]	[26]
Apraclonidine	DMO4PVE	Moderate	Additive CNS depression effects by the combination of Zonisamide and Apraclonidine.	Optic nerve disorder [9C40]	[30]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Zonisamide caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[15]
Flavoxate	DMKV4NL	Major	Increased risk of hyperpyrexia by the combination of Zonisamide and Flavoxate.	Pain [MG30-MG3Z]	[16]
Buprenorphine	DMPRI8G	Major	Additive CNS depression effects by the combination of Zonisamide and Buprenorphine.	Pain [MG30-MG3Z]	[31]
Orphenadrine	DMW542E	Major	Increased risk of hyperpyrexia by the combination of Zonisamide and Orphenadrine.	Parkinsonism [8A00]	[16]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Zonisamide caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[32]
Methylscopolamine	DM5VWOB	Major	Additive CNS depression effects by the combination of Zonisamide and Methylscopolamine.	Peptic ulcer [DA61]	[16]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Zonisamide caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[33]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Zonisamide caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[15]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Zonisamide caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[15]
Levomepromazine	DMIKFEL	Major	Increased risk of hyperpyrexia by the combination of Zonisamide and Levomepromazine.	Psychotic disorder [6A20-6A25]	[16]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Zonisamide and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[34]
Dexamethasone	DMMWZET	Moderate	Increased metabolism of Zonisamide caused by Dexamethasone mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[15]
Quetiapine	DM1N62C	Major	Additive CNS depression effects by the combination of Zonisamide and Quetiapine.	Schizophrenia [6A20]	[16]
Mesoridazine	DM2ZGAN	Major	Increased risk of hyperpyrexia by the combination of Zonisamide and Mesoridazine.	Schizophrenia [6A20]	[16]
Aripiprazole	DM3NUMH	Major	Increased risk of hyperpyrexia by the combination of Zonisamide and Aripiprazole.	Schizophrenia [6A20]	[16]
Iloperidone	DM6AUFY	Major	Increased risk of hyperpyrexia by the combination of Zonisamide and Iloperidone.	Schizophrenia [6A20]	[16]
Paliperidone	DM7NPJS	Major	Additive CNS depression effects by the combination of Zonisamide and Paliperidone.	Schizophrenia [6A20]	[16]
Molindone	DMAH70G	Major	Additive CNS depression effects by the combination of Zonisamide and Molindone.	Schizophrenia [6A20]	[16]
Thiothixene	DMDINC4	Major	Additive CNS depression effects by the combination of Zonisamide and Thiothixene.	Schizophrenia [6A20]	[16]
Asenapine	DMSQZE2	Major	Increased risk of hyperpyrexia by the combination of Zonisamide and Asenapine.	Schizophrenia [6A20]	[16]
Pimozide	DMW83TP	Major	Increased risk of hyperpyrexia by the combination of Zonisamide and Pimozide.	Schizophrenia [6A20]	[16]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Zonisamide caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[15]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Zonisamide caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[35]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Zonisamide caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[15]
Armodafinil	DMGB035	Minor	Increased metabolism of Zonisamide caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[36]
LEE011	DMMX75K	Moderate	Decreased metabolism of Zonisamide caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[15]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Zonisamide caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[37]
Chlorpheniramine	DM5URA2	Major	Increased risk of hyperpyrexia by the combination of Zonisamide and Chlorpheniramine.	Vasomotor/allergic rhinitis [CA08]	[16]
Trimeprazine	DMEMV9D	Major	Increased risk of hyperpyrexia by the combination of Zonisamide and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[16]
Acrivastine	DMTIGA0	Major	Additive CNS depression effects by the combination of Zonisamide and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[16]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
D&C red no. 28	E00491	6097185	Colorant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
FD&C red no. 4	E00356	62542	Colorant
Hydrazine yellow	E00409	164825	Colorant
Isopropyl alcohol	E00070	3776	Antimicrobial preservative; Solvent
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Ammonia	E00007	222	Alkalizing agent
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Butyl alcohol	E00011	263	Flavoring agent; Solvent
Eisenoxyd	E00585	56841934	Colorant
FD&C red no. 3	E00629	Not Available	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Magnesium stearate	E00208	11177	lubricant
Potassium hydroxide	E00233	14797	Alkalizing agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Water	E00035	962	Solvent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Zonisamide 100 mg capsule	100 mg	Oral Capsule	Oral
Zonisamide 25 mg capsule	25 mg	Oral Capsule	Oral
Zonisamide 50 mg capsule	50 mg	Oral Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] Zonisamide FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7047).
• [3] BDDCS applied to over 900 drugs
• [4] Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
• [5] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [6] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [7] Antiepileptic drugs and relapse after epilepsy surgery. Epileptic Disord. 2008 Sep;10(3):193-8.
• [8] Pharmacokinetics and drug interactions with zonisamide. Epilepsia. 2007 Mar;48(3):435-41.
• [9] Actual and Predicted Pharmacokinetic Interactions Between Anticonvulsants and Antiretrovirals.
• [10] Carbamazepine pharmacokinetics are not affected by zonisamide: in vitro mechanistic study and in vivo clinical study in epileptic patients. Epilepsy Res. 2004 Nov;62(1):1-11.
• [11] Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data. Eur J Clin Pharmacol. 1998 Apr;54(2):177-83.
• [12] Differential catalytic properties in metabolism of endogenous and exogenous substrates among CYP3A enzymes expressed in COS-7 cells. Biochim Biophys Acta. 1998 May 8;1380(3):297-304.
• [13] The role of mammalian intestinal bacteria in the reductive metabolism of zonisamide. J Pharm Pharmacol. 1997 Mar;49(3):253-6.
• [14] [The discovery of an antiparkinsonian drug, zonisamide]. Rinsho Shinkeigaku. 2010 Feb;50(2):67-73. doi: 10.5692/clinicalneurol.50.67.
• [15] Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, Kitada M "Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data." Eur J Clin Pharmacol 54 (1998): 177-83. [PMID: 9626925]
• [16] Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
• [17] Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ.
• [18] Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
• [19] Belcastro V, Costa C, Striano P "Levetiracetam-associated hyponatremia." Seizure 17 (2008): 389-90. [PMID: 18584781]
• [20] Cerner Multum, Inc. "Australian Product Information.".
• [21] Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
• [22] Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
• [23] Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
• [24] Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
• [25] Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
• [26] Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
• [27] Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
• [28] Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
• [29] Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
• [30] Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
• [31] Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8. [PMID: 3592200]
• [32] Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
• [33] Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
• [34] Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
• [35] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [36] Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
• [37] Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.